News | October 18, 2010

Italian Man Surpasses 1,000 Days Of Support With Artificial Heart

October 18, 2010 - A 54-year-old Italian man has become the first patient to surpass 1,000 days of support with an artificial heart while waiting for a matching donor heart. The patient was implanted with the SynCardia temporary Total Artificial Heart.

“Life is a wonderful present that has to be respected,” said patient Pietro Zorzetto. “The Total Artificial Heart allowed me to recover to a very healthy physical condition. I really want to thank the SynCardia Total Artificial Heart for these unexpected 1,000 days of life.”

Zorzetto was first admitted to Azienda Ospedaliera di Padova on Nov. 30, 2007, suffering from valvular cardiomyopathy. Two previous operations at a different hospital had failed to repair his failing heart. Less than a week later, Zorzetto made history when he became the first patient in Italy to be implanted with the SynCardia Total Artificial Heart.

“The Total Artificial Heart provides excellent cardiac output, which restored our patient to normal condition despite the fact he presented with severe multi-organ failure,” said professor Gino Gerosa. “The Total Artificial Heart in combination with the portable driver has been extremely effective in providing the patient with a good quality of life with excellent exercise capacity.”

Zorzetto has been at home since Feb. 4, 2008, when he was discharged from the hospital using a portable driver to power his artificial heart. On a typical day, he walks 10 km and then exercises for an additional 30 minutes in his gym at home to stay in shape for a transplant.

For more information: www.syncardia.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init